Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States

HIV Clinical Trials

Volumn 9, Issue 4, 2008, Pages 225-237

  Simpson, Kit N ^a   Roberts, Graeme ^b   Hicks, Charles B ^c   Finnern, Henrik W ^d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ICON PLC   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

AIDS; Cost effectiveness; HIV; Tipranavir; Treatment experienced

Indexed keywords

AMPRENAVIR; ENFUVIRTIDE; INDINAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; FEMALE; HEALTH CARE UTILIZATION; HEALTH STATUS; HIDDEN MARKOV MODEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; UNITED STATES; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PYRIDINES; PYRONES; QUALITY-ADJUSTED LIFE YEARS; RITONAVIR; UNITED STATES;

EID: 51949119174     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0904-225     Document Type: Article

References (44)

1. Richman DD., Morton SC, Wrind T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18(10):1393-1401.
2. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, US Department of Health and Human Services, AIDS info, January 29, 2008. Available at: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Last accessed June 27, 2008.
3. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection 2006 recommendations of the International AIDS Society-USA Panel. JAMA. 2006;296:827-843.
4. US Food and Drug Administration. Tipranavir product information. October 2007. Available at: http://www.fda.gov/cder/foi/label/2007/ 021814s003lbl.pdf. Last accessed June 27, 2008.
5. European Medicines Agency (EMEA). Tipranavir summary of product characteristics, April 2008. Available at: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/aptivus/H-631-PI-en.pdf. Last accessed June 27, 2008.
6. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1 -infected patients at 48 weeks in the randomized evaluation of strategic intervention in multi-drug resistant patients with tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466-475.
7. Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis. 2006;43:1347-1356.
8. Gathe J, Cooper DA, Farthing C, Jayaweera D et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 Trial. Clin Infect Dis. 2006;43:1337-1346.
9. Sax PE, Losina E, Weinstein MC, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005; 39:69-77.
10. Simpson K, Voit E, Goodman R, et al. Estimating the social and economic benefits of pharmaceutical innovation: modeling clinical trial results in HIV disease. Res Hum Capital Dev. 2001;14:175-198.
11. Freedberg KA, Scharfstein JA, Seage GR III, et al. Cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279:130-136.
12. Paltiel, DA, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med. 2005;352:586-595.
13. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440-450.
14. Hornberger J, Kilby, JM, Wintfield N, et al. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. AIDS Res Human Retroviruses. 2006;22:240-247.
15. Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004;5(5):294-304.
16. The AMCP format for formulary submissions, Version 2.1, April 2005. Available at: http://www.fmcpnet.org/data/resource/ Format-Version_2_1-Final_Final.pdf
17. WellPoint to mandate new formulary submission standards in 2009, September 28, 2007. Available at: http://www.thepinksheetdaily.com/ fdcreports/story/search/goTo Page.do. Last accessed June 27, 2008.
18. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:983-985.
19. The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51-62.
20. Loutfy MR, Walmsley SL, Mullin CM, et al. CD4+ cell increase predicts clinical benefit in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. J Infect Dis. 2005; 192:1407-1411.
21. Ghani AC, de Wolf F, Ferguson NM, et al. Surrogate markers for disease progression in treated HIV infection. J Acquir Immun Defic Syndr. 2001;28:226-231.
22. Ghani AC, Henley WE, Donnelly CA, et al. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS. 2001;15(9): 1133-1142.
23. Gebo KA, Gallant JE, Keruly JC, et al. Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Immun Defic Syndr. 2004; 36(5):1028-1033.
24. Weinstein MC, O'Brien B, Homberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modelling studies. Value Health. 2003;6(1):9-17.
25. Red Book 2007. Montwale, NJ: Thomson Healthcare; 2007.
26. Medical care component of the US consumer price index. Last modified June 18, 2008. Available at: http://www.bls.gov/cpi/cpi_dr.htm #2002. Last accessed June 27, 2008.
27. Dolan P. Modeling valuations for Euroqol Health States. Med Care. 1997;35:1095-1108.
28. Huang I, Wu AW, Finnern HW, et al. Health-related quality of life and tolerability in treatment-experienced HIV-1 infected patients on tipranavir versus comparator regimens. Antiviral Ther. 2008;13:15-25.
29. Russell LB, Siegel JE, Daniels N, et al. Cost-effectiveness analysis as a guide to resource allocation in health: roles and limitations. In: Gold MR, Siegel JE, Russel LB, et al., eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996:3-21.
30. Schackman BR, Goldie S, Freedberg KA, et al. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002;22:27-38.
31. Mrus JIM, Yi MS, Freedberg KA, et al. Utilities derived from visual analog scale scores in patients with HIV/AIDS. Med Decis Making. 2003;23:414-421.
32. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
33. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479-500.
34. O'Hagan A, McCabe C, Akeurst R, et al. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics. 2004;23:529-536.
35. Thompson SG, Nixon RM, Grieve R. Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study. J Health Econ. 2006;25(6): 1015-1028.
36. Boehringer Ingelheim data on file. RESIST 48-week meta-analysis study report. Doc. No. U06-3006.
37. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163:1637-1641.
38. The Antiretroviral Therapy (ART) Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679-686.
39. Zaccarelli M, Tozzi V, Forbici F, et al. Achieving undetectable HIV viral load after genotypic resistance test dramatically decreases HIV progression and survival even in more advanced patients. In: Program and abstracts of the 5th European HIV Drug Resistance Workshop; March 28-30, 2007; Cascais, Portugal. Abstract 93.
40. Bracciale L, Colafigli M, Di Giambenedetto S, et al. Reaching undetectable HIV RNA levels is an independent predictor of AIDS-free survival in patients with 3-Class Resistant HIV-1. In: Program and abstracts of the 5th European HIV Drug Resistance Workshop; March 28-30, 2007; Cascais, Portugal. Abstract 90.
41. Schackman BR, Gebo, KA, Walensky RP et al. The lifetime cost of current human immunodeficiency virus care in the United States Medical Care 2006;44(11):990-997.
42. WHO. Cost-effectiveness thresholds. Available at: http://www.who.int/ choice/costs/CER_thresholds/en/index.html. Last accessed June 27, 2008.
43. IMF. World Economic and Financial Surveys, World Economic Outlook Database, April 2006. Available at: http://imf.org/. Last accessed June 27, 2008.
44. Bell CA, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;322: 699-703.